Core Viewpoint - The approval of Tacrolimus extended-release capsules by the National Medical Products Administration of the People's Republic of China enhances the product line of the company in the field of immunosuppressive therapy [1] Group 1: Product Approval - The company has received a drug registration certificate for Tacrolimus extended-release capsules (0.5mg, 1mg) [1] - The product is considered to have passed the consistency evaluation of generic drug quality and efficacy [1] Group 2: Product Mechanism and Application - Tacrolimus is a macrolide immunosuppressant that inhibits the formation of cytotoxic lymphocytes responsible for transplant rejection [1] - The mechanism includes the suppression of T cell activation, proliferation of T helper cell-dependent B cells, and inhibition of lymphokine formation [1] - The product is indicated for preventing transplant rejection after kidney and liver transplants, as well as treating rejection that cannot be controlled by other immunosuppressive drugs [1] Group 3: Market Impact - The approval of this product will further enrich the company's product line in the field of immunosuppressive therapy [1]
石药集团(01093)：他克莫司缓释胶囊获药品注册批件